Literature DB >> 11096759

Cerebral Venous Thrombosis.

.   

Abstract

Cerebral venous thrombosis is a rare disorder with highly variable and nonspecific clinical presentations. For these reasons, specific treatment should be given only when the diagnosis has been firmly established. Etiologic diagnosis should begin in the emergency department to identify underlying conditions that require specific treatment. The mainstay of treatment is anticoagulation with heparin, even in the case of cerebral hemorrhage, followed as soon as possible by oral anticoagulant administration. The optimal duration of oral anticoagulation has not been established. By analogy with systemic venous thrombosis, it should be prolonged 3 to 6 months. When a high risk of recurrence is present, treatment should be continued until the risk disappears. In contrast to arterial stroke, complete recovery of prolonged or severe neurologic deficit is possible, justifying initiation of anticoagulation even when the clinical situation seems desperate. For the same reason, aggressive treatment of intracranial hypertension and seizures or status epilepticus is warranted. Screening for extraneurologic venous thrombosis should be done by means of clinical examination and, if necessary, specific imaging procedures. Local thrombolysis is not yet of proven efficacy and safety. It can be used in patients with clinical worsening related to documented extension of the venous thrombosis despite anticoagulation and in the absence of cerebral hematoma. Surgical treatment is limited to external ventricular drainage and suboccipital craniotomy in the very rare cases of cerebellar vein thrombosis with edematous cerebellar infarct.

Entities:  

Year:  2000        PMID: 11096759     DOI: 10.1007/s11940-000-0051-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  35 in total

1.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

2.  Deep cerebral venous thrombosis: imaging in eight cases.

Authors:  F Lafitte; M Boukobza; J P Guichard; D Reizine; F Woimant; J J Merland
Journal:  Neuroradiology       Date:  1999-06       Impact factor: 2.804

3.  Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group.

Authors:  S F de Bruijn; J Stam; M M Koopman; J P Vandenbroucke
Journal:  BMJ       Date:  1998-02-21

4.  Heparin treatment in sinus venous thrombosis.

Authors:  K M Einhäupl; A Villringer; W Meister; S Mehraein; C Garner; M Pellkofer; R L Haberl; H W Pfister; P Schmiedek
Journal:  Lancet       Date:  1991-09-07       Impact factor: 79.321

5.  Factor V Leiden mutation in cerebral venous thrombosis.

Authors:  M Zuber; P Toulon; L Marnet; J L Mas
Journal:  Stroke       Date:  1996-10       Impact factor: 7.914

6.  Diffusion-weighted magnetic resonance imaging in a case of cerebral venous thrombosis.

Authors:  J C Corvol; C Oppenheim; R Manaï; M Logak; D Dormont; Y Samson; C Marsault; G Rancurel
Journal:  Stroke       Date:  1998-12       Impact factor: 7.914

7.  Urokinase treatment of sagittal sinus thrombosis with venous hemorrhagic infarction.

Authors:  S E Kasner; J H Gurian; J C Grotta
Journal:  J Stroke Cerebrovasc Dis       Date:  1998 Nov-Dec       Impact factor: 2.136

Review 8.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

9.  Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients.

Authors:  M Preter; C Tzourio; A Ameri; M G Bousser
Journal:  Stroke       Date:  1996-02       Impact factor: 7.914

10.  High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.

Authors:  I Martinelli; E Sacchi; G Landi; E Taioli; F Duca; P M Mannucci
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245

View more
  4 in total

Review 1.  Pregnancy and stroke.

Authors:  Mohammed Pathan; Steven J Kittner
Journal:  Curr Neurol Neurosci Rep       Date:  2003-01       Impact factor: 5.081

2.  Uncontrolled seizures resulting from cerebral venous sinus thrombosis complicating neurobrucellosis.

Authors:  Fardin Faraji; Farshid Didgar; Afsoon Talaie-Zanjani; Abolfazl Mohammadbeigi
Journal:  J Neurosci Rural Pract       Date:  2013-07

3.  Cerebral Venous Thrombosis.

Authors:  Valérie Biousse; Frank Tong; Nancy J. Newman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-07

4.  Cerebral Venous Thrombosis.

Authors:  Valérie Biousse; Frank Tong; Nancy J. Newman
Journal:  Curr Treat Options Neurol       Date:  2003-09       Impact factor: 3.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.